[1]封 慧.阿托伐他汀联合氯吡格雷治疗急性冠脉综合征疗效及对患者血清脑钠尿肽及心肌酶谱指标的影响[J].陕西医学杂志,2023,52(7):894-897，901.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.027]
　FENG Hui.Efficacy of atorvastatin combined with clopidogrel in treatment of acute coronary syndrome and effects on serum BNP,cTnI and myocardial enzymes indexes in patients[J].,2023,52(7):894-897，901.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.027]
点击复制

阿托伐他汀联合氯吡格雷治疗急性冠脉综合征疗效及对患者血清脑钠尿肽及心肌酶谱指标的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年7期
页码:
894-897，901
栏目:
药物与临床
出版日期:
2023-07-05

文章信息/Info

Title:
Efficacy of atorvastatin combined with clopidogrel in treatment of acute coronary syndrome and effects on serum BNP,cTnI and myocardial enzymes indexes in patients
作者:
封 慧
(四川大学华西医院急诊科,四川 成都 610041)
Author(s):
FENG Hui
(Department of Emergency Medicine,West China Hospital,Sichuan University,Chengdu 610041,China)
关键词:
急性冠脉综合征;  阿托伐他汀;  氯吡格雷;  心肌酶谱;  血清脑钠尿肽;  脂代谢;  血小板功能
Keywords:
Acute coronary syndrome;  Atorvastatin;  Clopidogrel;  Myocardial enzymes;  Serum brain natriuretic peptide;  Lipid metabolism;  Platelet function
分类号:
R 543.3
DOI:
DOI:10.3969/j.issn.1000-7377.2023.07.027
文献标志码:
A
摘要:
目的:探究阿托伐他汀联合氯吡格雷对急性冠脉综合征(ACS)患者血清脑钠尿肽(BNP)、心肌酶谱相关指标的影响及其临床疗效。方法:回顾性分析110例ACS患者的临床资料,患者均接受经皮冠状动脉介入(PCI)治疗,根据术后用药方式的不同将其分为观察组(n=55)和对照组(n=55)。其中对照组患者给予氯吡格雷治疗,观察组在对照组的基础上加用阿托伐他汀进行治疗,两组患者均连续治疗2个月。对比两组患者治疗2个月后临床疗效,比较两组患者治疗前及治疗2个月后心功能血清学指标[血清脑钠尿肽(BNP)、B型钠尿肽前体(NT-proBNP)]、心肌酶谱[肌钙蛋白(cTnI)、肌钙蛋白-T(cTn-T)、肌酸激酶同工酶MB质量(CK-MB mass)、肌红蛋白(Mb)]、脂代谢水平[甘油三酯(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)]、血小板功能[血小板最大聚集率(MPAR)、血小板反应指数(PRI)],并统计两组患者治疗期间不良心血管事件发生率。结果:治疗两个月后,观察组患者临床治疗有效率(87.3%)明显高于对照组(70.9%)(P<0.05); 治疗两个月后,两组患者BNP、NT-proBNP、心肌酶谱、血小板功能各项指标、TG、LDL-C水平均较治疗前明显降低,且观察组明显低于对照组(均P<0.05); 治疗2个月后,两组患者HDL-C水平较治疗前明显上升,且观察组明显高于对照组(P<0.05); 治疗期间,观察组患者不良心血管事件总发生率(5.5%)明显低于对照组(18.2%)(P<0.05)。结论:阿托伐他汀联合氯吡格雷应用于ACS患者PCI术后治疗中,可有效提升患者心脏功能,缓解心肌受损状态,对改善患者脂代谢水平及血小板功能具有积极影响,且可有效降低患者不良心血管事件发生率。
Abstract:
Objective:To explore the effects of atorvastatin combined with clopidogrel on serum brain natriuretic peptide(BNP)and myocardial enzymes-related indexes in patients with acute coronary syndrome(ACS)and clinical efficacy.Methods:The clinical data of 110 patients with ACS were retrospectively analyzed.All patients received percutaneous coronary intervention(PCI)and were divided into observation group(55 cases)and control group(55 cases)according to the different postoperative medication methods.The control group was treated with clopidogrel and the observation group was additionally given atorvastatin on the basis of the control group.Both groups of patients were treated continuously for 2 months.The clinical efficacy after 2 months of treatment,cardiac function serological indexes [serum brain natriuretic peptide(BNP),N-terminal pro-B-type natriuretic peptide(NT-proBNP)],myocardial enzymes [cardiac troponin(cTnI),cardiac troponin T(cTn-T),creatine kinase isoenzyme MB mass(CK-MB),myoglobin(Mb)],lipid metabolism indexes [triglyceride(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)]and platelet function indexes [maximum platelet aggregation rate(MPAR),platelet response index(PRI)]before treatment and after 2 months of treatment were compared between the two groups,and the incidence rates of adverse cardiovascular events in the two groups during treatment were statistically analyzed.Results:After 2 months of treatment,the effective rate of clinical treatment in observation group(87.3%)was significantly higher than that(70.9%)in control group(P<0.05).After 2 months of treatment,the BNP,NT-proBNP,myocardial enzymes,platelet function indexes,TG and LDL-C in both groups were significantly reduced in comparison with those before treatment,and the indexes in observation group were significantly lower than those in control group(all P<0.05).The HDL-C level in the two groups after 2 months of treatment was significantly increased in comparison with that before treatment,and the level in observation group was significantly higher in comparison with that in control group(all P<0.05).During treatment,the total incidence rate of adverse cardiovascular events in observation group(5.5%)was significantly lower than that(18.2%)in control group(P<0.05).Conclusion:Atorvastatin combined with clopidogrel in the treatment of patients with ACS after PCI can effectively enhance the cardiac function and relieve the myocardial damage status,and it has a positive effect in improving the lipid metabolism and platelet function of patients,and it can effectively reduce the incidence rates of adverse cardiovascular events.

参考文献/References:

[1] 王凯阳,闵 轩,宁 怡,等.GRACE评分联合血栓弹力图对急性冠脉综合征患者主要心血管不良事件的早期预测价值[J].石河子大学学报:自然科学版,2022,40(3):383-389.
[2] 万招飞,李晓莉,王新宏,等.A20/NLRP3炎症小体信号通路在急性冠脉综合征PCI患者冠脉无复流中的作用[J].山西医科大学学报,2022,53(9):1065-1069.
[3] 钟云川,何 花,黄 乐.PCI术后瑞舒伐他汀钙片联合替格瑞洛对急性冠脉综合征患者心功能、心肌损伤标志物及hs-CRP、Hcy的影响[J].临床和实验医学杂志,2022,21(10):1034-1038.
[4] 蔡今伦,王立中,贾耀文,等.尼可地尔联合氯吡格雷对急性冠脉综合征患者PCI术后血小板活化指标及血清BNP、MMP-9的影响[J].中国医院用药评价与分析,2022,22(9):1105-1108.
[5] 吕永飞,陈爱莲.益心康泰胶囊治疗冠心病经皮冠状动脉介入术术后疗效及对患者血流变、血管内皮功能的影响[J].陕西中医,2019,40(6):714-717.
[6] 中国医师协会急诊医师分会,中华医学会心血管病学分会,中华医学会检验医学分会.急性冠脉综合征急诊快速诊疗指南[J].中华急诊医学杂志,2016,25(4):397-404.
[7] 梁 峰,沈珠军,方 全,等.2014年美国心脏协会/美国心脏病学院关于非ST抬高急性冠脉综合征患者治疗指南(二)[J].中国心血管病研究,2015,13(8):689-692.
[8] 杨 旭,贾亚丹,张云飞,等.UA、DD及HCY水平对急性冠脉综合征患者PCI术后再次狭窄的影响[J].分子诊断与治疗杂志,2021,13(1):91-94,98.
[9] 庞胜峰,张 晶,吴宁宁,等.急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J].中国临床药理学与治疗学,2022,27(9):1004-1009.
[10] 李 佳,李雪莲,朱铁艳,等.影响冠心病患者PCI术后预后的因素及预后预测模型建立[J].甘肃科学学报,2022,34(4):49-54.
[11] 李中轩,白 鹏,刘长福.不同剂量替罗非班对急性冠脉综合征患者PCI术后疗效及安全性观察[J].中国循证心血管医学杂志,2022,14(7):848-850.
[12] 刘薇拉,刘丹丹.BNP/NT-proBNP检测在冠心病中的应用研究进展[J].中西医结合心脑血管病杂志,2020,18(22):3796-3798.
[13] 张国忠.心肌酶谱与cTnI、BNP联合检测在冠心病患者危险分层及手术效果的评估价值[J].中国医药导刊,2022,24(7):678-682.
[14] Khalighfard S,Khori V,Alizadeh AM,et al.Dual effects of atorvastatin on angiogenesis pathways in the differentiation of mesenchymal stem cells[J].Eur J Pharmacol,2021,907:174281.
[15] Sun L,Zhang Y,Zhang J,et al.Atorvastatin improves the proliferation and migration of endothelial progenitor cells via the miR-221/VEGFA axis[J].Biosci Rep, 2020,40(11):20193053.
[16] Sato K,Takahashi J,Hao K,et al.Temporal trends in the prevalence and outcomes of geriatric patients with acute myocardial infarction in Japan-a report from the Miyagi AMI Registry Study[J].J Cardiol,2020,75(5):465-472.
[17] 王 蒂,王莹莹,张艺馨.阿托伐他汀强化降脂对CABG患者的影响[J].临床心电学杂志,2022,31(3):207-210.
[18] Cirillo P,Taglialatela V,Pellegrino G,et al.Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel[J].J Thromb Thrombolysis,2020,50(2):468-472.
[19] 王晓蕊,苗昌荣,郑志君,等.血小板聚集率指导的抗血小板药治疗对急性冠脉综合征患者经皮冠状动脉介入治疗术后近期和远期预后的影响[J].中国医院用药评价与分析,2021,21(7):804-807,812.
[20] 张 琳,曹甜甜,吕俊刚,等.瑞舒伐他汀与阿托伐他汀对脑小血管病患者血脂、血小板聚集率、炎症因子水平及认知功能的比较[J].脑与神经疾病杂志,2022,30(2):117-120.

相似文献/References:

[1]段继源,王光哲,曹艳,等.胰岛素强化治疗对急性冠脉综合征合并糖尿病患者PCI术后血小板功能的影响[J].陕西医学杂志,2016,(10):1411.
[2]郭 华,白 洁,梁乐乐,等.胸痛血管三联合成像Meta分析*[J].陕西医学杂志,2019,(10):1402.
[3]严晓华,王 娜,马 娟,等.阿托伐他汀对小鼠川崎病的治疗作用及机制研究[J].陕西医学杂志,2022,51(6):672.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.007]
　YAN Xiaohua,WANG Na,MA Juan,et al.Therapeutic effect and mechanism of atorvastatin on Kawasaki disease mice[J].,2022,51(7):672.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.007]
[4]刘 放,谈 红,晋 群,等.阿托伐他汀改善急性心肌梗死后左室收缩功能实验研究[J].陕西医学杂志,2022,51(10):1196.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.005]
　LIU Fang,TAN Hong,JIN Qun,et al.Mechanism of atorvastatin improving the left ventricular systolic function after acute myocardial infarction in rabbits[J].,2022,51(7):1196.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.005]
[5]梁 蒙,杨 雀,陈伟国,等.达格列净联合阿托伐他汀治疗糖尿病心肌病疗效及对患者Klotho和心室重构的影响[J].陕西医学杂志,2023,52(7):898.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.028]
　LIANG Meng,YANG Que,CHEN Weiguo,et al.Efficacy of dapagliflozin combined with atorvastatin in treatment of diabetes cardiomyopathy and effects on Klotho and ventricular remodeling in patients[J].,2023,52(7):898.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.028]

备注/Memo

备注/Memo:
基金项目:四川省科技计划项目(2021YFS0189)
更新日期/Last Update: 2023-07-05